Search
Alector Inc
ALECAdd to Watchlist
2.060USD
+0.050+2.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
228.71MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.49%
5 Days
+10.75%
1 Month
+13.81%
6 Months
+34.64%
Year to Date
+32.05%
1 Year
+36.42%
Key Figures
2.020Open
2.145High
394.06KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.35%Turnover Ratio
2.010Prev. Close
1.995Low
525.03KTurnover
LossP/E Static
22.03P/B
0.00%Div Yield TTM
-38.69%ROA
3.40052wk High
0.58Volume Ratio
-119.05MNet Profit
111.03MShares
-1.1879EPS TTM
0.62Beta
-238.85%ROE
1.09052wk Low
7.46%Amplitude
100.00%Gross Margin
228.71MMarket Cap
2.10Reward/Risk
5.26%Risk Rate
TradingKey Stock Score of Alector Inc
Currency: USD Updated: 2026-07-02Key Insights
Alector Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 138 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.10.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alector Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Alector Inc Highlights
StrengthsRisks
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 21.05M.
Fairly Valued
The company’s latest PE is -1.73, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 89.88M shares, decreasing 26.83% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 33.31K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.15.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
3.100
Target Price
+54.23%
Upside Space
Alector Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alector Inc Info
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Ticker SymbolALEC
CompanyAlector Inc
CEORosenthal (Arnon)
Websitehttps://alector.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Alector Inc (ALEC)?
The current price of Alector Inc (ALEC) is 2.06.
What is the symbol of Alector Inc?
The ticker symbol of Alector Inc is ALEC.
What is the 52-week high of Alector Inc?
The 52-week high of Alector Inc is 3.40.
What is the 52-week low of Alector Inc?
The 52-week low of Alector Inc is 1.09.
What is the market capitalization of Alector Inc?
The market capitalization of Alector Inc is 228.71M.
Is Alector Inc (ALEC) currently rated as Buy, Hold, or Sell?
According to analysts, Alector Inc (ALEC) has an overall rating of signal_hold, with a price target of 3.10.
What is the Earnings Per Share (EPS TTM) of Alector Inc (ALEC)?
The Earnings Per Share (EPS TTM) of Alector Inc (ALEC) is -1.39.